Organon (OGN) Other financing activities (2020 - 2021)
Organon (OGN) posted Other financing activities of -$112.0 million for Q2 2021, up 54.1% on a QoQ basis from -$244.0 million in Q1 2021, and down 202.75% year-over-year from $109.0 million in Q2 2020.
Powered by 
Analysis
Organon (OGN) Other financing activities (2020 - 2021) Analysis & Trends
Organon has reported Other financing activities for 2 years, with the latest figure at -$112.0 million in Q2 2021.
- On a quarterly basis, Other financing activities fell 202.75% year-over-year to -$112.0 million in Q2 2021; TTM through Mar 2022 was -$112.0 million, a 77.0% increase from a year earlier, with the FY2021 full-year figure at -$356.0 million, down 132.68% from the prior year.
- Other financing activities was -$112.0 million for Q2 2021 at Organon, up from -$244.0 million in the prior quarter.
- The five-year high for Other financing activities was $109.0 million in Q2 2020, with the low at -$324.0 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Organon | 3.58 Bn | 2.45 Bn | 847.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -112.00 Mn |
| Mar 31, 2021 | -244.00 Mn |
| Dec 31, 2020 | -324.00 Mn |
| Sep 30, 2020 | -28.00 Mn |
| Jun 30, 2020 | 109.00 Mn |
| Mar 31, 2020 | 90.00 Mn |